EMILY LITTLE: Open Payments
NPI 1891046694 · COLUMBUS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,927 in 92 payments from 18 companies in 2025. Trend: 2023 $1,780 · 2024 $1,580 · 2025 $1,927
Food & beverage: $1,927
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $547 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 15 | $331 |
| Ardelyx, Inc. | 14 | $305 |
| Janssen Biotech, Inc. | 8 | $151 |
| Madrigal Pharmaceuticals | 5 | $138 |
| Ipsen Biopharmaceuticals, Inc | 3 | $65 |
| Novo Nordisk Inc | 2 | $57 |
| Phathom Pharmaceuticals, Inc. | 2 | $44 |
| Gilead Sciences, Inc. | 2 | $43 |
| Aimmune Therapeutics, Inc. | 2 | $41 |
Products named: XIFAXAN, IBSRELA, RINVOQ, TREMFYA, REZDIFFRA, SKYRIZI, CREON, DUPIXENT.
Industry payments across GA — which companies pay providers there.
